Immunomedics INC (IMMU) Market Valuation Rose While Venbio Select Advisor LLC Upped Position

February 15, 2018 - By Peter Erickson

Investors sentiment increased to 1.65 in Q3 2017. Its up 0.24, from 1.41 in 2017Q2. It is positive, as 16 investors sold IMMU shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported. Tiaa Cref Invest Mgmt Ltd has 272,375 shares for 0% of their portfolio. Manufacturers Life Communication The has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU). Geode Cap Lc holds 0% in Immunomedics, Inc. (NASDAQ:IMMU) or 911,926 shares. Driehaus Mgmt Ltd Liability Corporation reported 0.43% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Highbridge Mgmt Ltd Liability Co holds 0.15% or 739,371 shares. Noven Group Inc invested in 14,000 shares. Nicholas Inv Prtnrs LP holds 0.32% or 334,279 shares. Royal Retail Bank Of Canada has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Panagora Asset owns 649,601 shares. Laurion Mgmt Limited Partnership reported 44,115 shares or 0% of all its holdings. Morgan Stanley has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 439,420 shares. Gotham Asset accumulated 0.08% or 369,295 shares. 500 are owned by Thompson Davis And Company. 20,791 are held by D E Shaw &. Balyasny Asset Management Limited Liability Company owns 235,687 shares.

Since August 21, 2017, it had 0 insider purchases, and 6 sales for $2.10 million activity. GOLDENBERG DAVID M also sold $252,750 worth of Immunomedics, Inc. (NASDAQ:IMMU) shares.

Venbio Select Advisor Llc increased its stake in Immunomedics Inc (IMMU) by 40.54% based on its latest 2017Q3 regulatory filing with the SEC. Venbio Select Advisor Llc bought 4.25M shares as the company’s stock rose 37.64% with the market. The institutional investor held 14.74M shares of the health care company at the end of 2017Q3, valued at $206.06 million, up from 10.49M at the end of the previous reported quarter. Venbio Select Advisor Llc who had been investing in Immunomedics Inc for a number of months, seems to be bullish on the $2.67B market cap company. The stock increased 0.56% or $0.09 during the last trading session, reaching $16.09. About 746,228 shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since February 15, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Venbio Select Advisor Llc, which manages about $380.08M and $1.29B US Long portfolio, decreased its stake in Immunomedics Inc (Call) (NASDAQ:IMMU) by 9.61M shares to 875,000 shares, valued at $6.30M in 2017Q3, according to the filing.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $16 target in Monday, October 9 report. The company was downgraded on Tuesday, June 21 by Wells Fargo. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Wednesday, December 6 by Jefferies. The firm has “Buy” rating by Cowen & Co given on Monday, July 24. The company was maintained on Thursday, August 17 by Jefferies. The rating was downgraded by Wells Fargo on Friday, December 4 to “Market Perform”. Cowen & Co maintained Immunomedics, Inc. (NASDAQ:IMMU) on Wednesday, August 16 with “Buy” rating. Jefferies maintained Immunomedics, Inc. (NASDAQ:IMMU) on Tuesday, September 19 with “Buy” rating. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Hold” rating given on Wednesday, July 29 by Jefferies. Jefferies upgraded the stock to “Buy” rating in Friday, May 6 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.